Clinical Trial

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

Name: Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin — clinical trial record (NCT07754331)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to investigate the effect of HD on single oral dose PK, safety, and tolerability of balcinrenone/dapagliflozin to male and female participants with kidney failure on intermittent HD.

Trial Details

NCT Number	NCT07754331
Lead Sponsor	AstraZeneca Collaborators: Fortrea
Conditions	Kidney Failure
Enrollment	10 participants
Start Date	2026-08-05
Primary Completion	2026-12-02 (estimated)
Study Completion	2026-12-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-10